RECRUITING

Herbal Evaluation Of Artemisia Annua For Small Intestinal Bacterial Overgrowth

Description

Small intestinal bacterial overgrowth (SIBO) can cause symptoms like bloating, stomach pain, and changes in bowel movements, significantly affecting quality of life. Many people with irritable bowel syndrome (IBS) also have SIBO, and there is growing recognition of how important it is to address this condition. Artemisia annua has shown potential in managing SIBO based on early reports and studies suggesting it can fight bacteria like \*E. coli\* and \*Klebsiella\*, which are linked to a type of SIBO that produces hydrogen gas. This study aims to test if Artemisia annua is safe and well-tolerated for adults with hydrogen-type SIBO. Over five weeks, participants will take either 5 grams of dried Artemisia annua leaves or a placebo. Researchers will monitor safety through blood tests, vital signs, and adverse events, and they will assess symptom changes using questionnaires and breath tests. The trial will include up to 32 participants from the Portland, Oregon area. Participants will be randomly assigned to treatment groups, and neither they, the researchers, nor the test administrators will know who is receiving the herb or the placebo. Results will be analyzed using standard statistical methods. This study addresses the lack of research on herbal treatments for SIBO. If successful, the findings could lead to larger studies and help expand treatment options for people with SIBO.

Conditions

Small Intestinal Bacterial Overgrowth Syndrome (SIBO)
Talk to us

Related Conditions:

Small Intestinal Bacterial Overgrowth Syndrome (SIBO)

Study Overview

On this page

Study Details

Study overview

Small intestinal bacterial overgrowth (SIBO) can cause symptoms like bloating, stomach pain, and changes in bowel movements, significantly affecting quality of life. Many people with irritable bowel syndrome (IBS) also have SIBO, and there is growing recognition of how important it is to address this condition. Artemisia annua has shown potential in managing SIBO based on early reports and studies suggesting it can fight bacteria like \*E. coli\* and \*Klebsiella\*, which are linked to a type of SIBO that produces hydrogen gas. This study aims to test if Artemisia annua is safe and well-tolerated for adults with hydrogen-type SIBO. Over five weeks, participants will take either 5 grams of dried Artemisia annua leaves or a placebo. Researchers will monitor safety through blood tests, vital signs, and adverse events, and they will assess symptom changes using questionnaires and breath tests. The trial will include up to 32 participants from the Portland, Oregon area. Participants will be randomly assigned to treatment groups, and neither they, the researchers, nor the test administrators will know who is receiving the herb or the placebo. Results will be analyzed using standard statistical methods. This study addresses the lack of research on herbal treatments for SIBO. If successful, the findings could lead to larger studies and help expand treatment options for people with SIBO.

Herbal Evaluation Of Artemisia Annua For Small Intestinal Bacterial Overgrowth: A Phase I/II Triple-Masked, Placebo-Controlled Trial

Herbal Evaluation Of Artemisia Annua For Small Intestinal Bacterial Overgrowth

Condition
Small Intestinal Bacterial Overgrowth Syndrome (SIBO)
Intervention / Treatment

-

Contacts and Locations

Portland

Helfgott Research Institute - National University of Natural Medicine, Portland, Oregon, United States, 97201

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Adults 18 years of age or older
  • * IBS-SSS score \>175
  • * Meets North American Consensus criteria for H2 SIBO
  • * Willing to take Artecinua™ or placebo as a dietary supplement for 5 weeks
  • * Willing to have two lactulose breath tests and do the prep diet 24 hours before and fast overnight before the test
  • * Willing to have three blood drawstests and fast overnight before the draw
  • * Able to speak, read, and understand English
  • * Able to provide informed consent
  • * For individuals of child-bearing potential, willing to use an intrauterine device or two other concurrent forms of birth control to prevent pregnancy while enrolled
  • * Use of antibiotic pharmaceuticals or supplements 14 days before baseline breath test
  • * Initiation of change in diet, medication, or supplement regime within 30 days
  • * Hospitalization within the past 3 months
  • * Women who are breastfeeding, pregnant, or planning pregnancy in the next 4 months
  • * Allergies to any of the ingredients in the study products.
  • * Individuals with chronic kidney or liver disease, cancer, colorectal disease and/or other rare disorders that at the discretion of the PI or Clinical \*Investigator may impact their safety or confound trial results
  • * The use of any high-risk medications with narrow therapeutic indices metabolized by CYP450 enzymes: Warfarin (CYP2C9), Tacrolimus/Cyclosporine (CYP3A4), Efavirenz (CYP2B6), and Codeine (CYP2D6).
  • * Drugs requiring activation for efficacy: Clopidogrel (CYP2C19), Codeine (CYP2D6), and Tamoxifen (CYP2D6) (citations).
  • * GFR: \<30 mL/min/1.73m²
  • * Hepatitis from any cause.
  • * Excessive alcohol use (\> seven drinks/week in women and \> fourteen in men).
  • * Hepatic (ALT, AST, bilirubin) and renal (creatinine, estimated GFR) parameters outside of normal range at screening.

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

National University of Natural Medicine,

Study Record Dates

2026-01